China Regenerative Medicine International Limited (HKG:8158)
0.3100
+0.0100 (3.33%)
Oct 8, 2026, 9:36 AM HKT
HKG:8158 Revenue
China Regenerative Medicine International had revenue of 41.73M HKD in the half year ending June 30, 2026, a decrease of -30.19%. This brings the company's revenue in the last twelve months to 86.40M, up 48.39% year-over-year. In the year 2025, China Regenerative Medicine International had annual revenue of 72.06M, down -20.48%. That makes China Regenerative Medicine International the world's 36,863rd largest company by revenue and 2,246th in Hong Kong.
Revenue (ttm)
86.40M
Revenue Growth
+48.39%
P/S Ratio
1.06
Revenue / Employee
2.62M
Employees
33
Market Cap
94.32M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 72.06M | -18.56M | -20.48% |
| Dec 31, 2024 | 90.62M | 21.13M | 30.41% |
| Dec 31, 2023 | 69.49M | 27.95M | 67.29% |
| Dec 31, 2022 | 41.54M | -241.36M | -85.32% |
| Dec 31, 2021 | 282.90M | 100.76M | 55.32% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Uni-Bio Science Group | 549.77M |
| 3D Medicines | 412.66M |
| Cutia Therapeutics | 383.95M |
| Kintor Pharmaceutical | 90.90M |
| Wuhan YZY Biopharma | 67.26M |
| Shanghai Bio-heart Biological Technology | 44.39M |
| Brii Biosciences | 40.23M |
| Transcenta Holding | 32.70M |